Charlie Rowland

Charlie Rowland is an accomplished biotechnology executive with extensive experience serving on the boards of multiple companies in the pharmaceutical and biopharmaceutical sectors. Currently a Board Member and Audit Committee Chair at Generation Bio since August 2018, Rowland also holds similar positions at Nabriva Therapeutics plc and Viking Therapeutics, Inc. Since January 2015 and July 2017, respectively. Rowland has previously contributed to the strategic direction of companies such as Orchard Therapeutics, Blueprint Medicines, and PsiOxus Therapeutics, among others. Rowland's leadership includes serving as President & CEO at Aurinia Pharmaceuticals, enhancing the company's focus on global nephrology. Education includes an MBA in Finance from Rutgers University and a BS in Accounting from Saint Joseph's University.